DCTH:NASDAQ
Delcath Systems Inc
$15.08
arrow_upward
+0.27%(+0.040) 1D
Oct 9, 11:32:51 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DCTH...
Open
$15.07
High
$15.27
Low
$14.94
Mkt. cap
523.26M
Avg. vol.
365.26K
Volume
42.62K
P/E ratio
2,468.09
52-wk high
$17.42
52-wk low
$8.12
EPS
$0.01
Beta
0.60
Shares outstanding
34.70M
No. of employees
156
Open
$15.07
High
$15.27
Low
$14.94
Mkt. cap
523.26M
Avg. vol.
365.26K
Volume
42.62K
P/E ratio
2,468.09
52-wk high
$17.42
52-wk low
$8.12
EPS
$0.01
Beta
0.60
Shares outstanding
34.70M
No. of employees
156
News stories
From web sources and news partners
The Manila Times
·
25 minutes ago
IT Tech Packaging, Inc. Announces NYSE Regulation Acceptance of Extension Request; Listing Continued Pursuant to Extension Through April 15, 2027
Yahoo Finance
·
24 minutes ago
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
MarketBeat
·
14 minutes ago
Vodafone Group (NASDAQ:VOD) Shares Gap Down - Time to Sell?
Seeking Alpha
·
39 minutes ago
S&P 500’s top five stocks match market cap of bottom 434, Batnick says
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees156
Founded1988
HeadquartersQueensbury, New York, United States
SectorMedical device
Websitedelcath.com